1-5 of 5
Christophe Louvet
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial

Julien Taieb, Valérie Taly, Julie Henriques, Camille Bourreau, Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Christophe Louvet, Céline Lepere, May Mabro, Joëlle Egreteau, Olivier Bouche, Claire Mulot, Katia Hormigos, Kariman Chaba, Thibault Mazard, Aimery de Gramont, Dewi Vernerey, Thierry André, Pierre Laurent-Puig
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5638–5646.
https://doi.org/10.1158/1078-0432.CCR-21-0271
Published: 15 October 2021
View articletitled, Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial
Open the PDF for Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial in another window
Includes: Supplementary data
Journal Articles

CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Benoit You, Patrick Robelin, Michel Tod, Christophe Louvet, Jean-Pierre Lotz, Sophie Abadie-Lacourtoisie, Michel Fabbro, Christophe Desauw, Nathalie Bonichon-Lamichhane, Jean-Emmanuel Kurtz, Philippe Follana, Marianne Leheurteur, Francesco Del Piano, Gwénael Ferron, Gaëtan De Rauglaudre, Isabelle Ray-Coquard, Pierre Combe, Annick Chevalier-Place, Florence Joly, Alexandra Leary, Eric Pujade-Lauraine, Gilles Freyer, Olivier Colomban
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4625–4632.
https://doi.org/10.1158/1078-0432.CCR-20-0054
Published: 01 September 2020
View articletitled, CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Open the PDF for CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial in another window
Includes: Supplementary data
Journal Articles

Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma

Raphaël Maréchal, Jean-Baptiste Bachet, Annabelle Calomme, Pieter Demetter, Jean Robert Delpero, Magali Svrcek, Jérôme Cros, Armelle Bardier-Dupas, Francesco Puleo, Geneviève Monges, Pascal Hammel, Christophe Louvet, François Paye, Philippe Bachelier, Yves Patrice Le Treut, Jean-Christophe Vaillant, Alain Sauvanet, Thierry André, Isabelle Salmon, Jacques Devière, Jean-François Emile, Jean-Luc Van Laethem
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (5): 1215–1224.
https://doi.org/10.1158/1078-0432.CCR-14-0667
Published: 01 March 2015
View articletitled, Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma
Open the PDF for Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study

Daniel J. Sargent, Qian Shi, Sharlene Gill, Christophe Louvet, Richard B. Everson, Udo Kellner, Thomas E. Clancy, J. Marc Pipas, Murray B. Resnick, Michael O. Meyers, Tsung-Teh Wu, David Huntsman, Pierre Validire, Umar Farooq, Emily S. Pavey, Guillaume Beaudry, Jean-Francois Haince, Yves Fradet
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (16): 4361–4369.
https://doi.org/10.1158/1078-0432.CCR-13-2659
Published: 13 August 2014
View articletitled, Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study
Open the PDF for Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study in another window
Includes: Supplementary data
Journal Articles

Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy

Aziz Zaanan, Jean-François Fléjou, Jean-François Emile, Guetz Gaëtan Des, Peggy Cuilliere-Dartigues, David Malka, Cédric Lecaille, Pierre Validire, Christophe Louvet, Philippe Rougier, Aimery de Gramont, Franck Bonnetain, Françoise Praz, Julien Taïeb
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7470–7478.
https://doi.org/10.1158/1078-0432.CCR-11-1048
Published: 30 November 2011
View articletitled, Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy
Open the PDF for Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy in another window
Includes: Supplementary data